thalidomide has been researched along with Granulomas in 15 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is an immunomodulatory agent that acts to inhibit production of tumor-necrosis factor-alpha (TNF-alpha), an important mediator in CNS inflammation, by enhancing TNF-alpha mRNA degradation." | 5.34 | Thalidomide for acute treatment of neurosarcoidosis. ( Hammond, ER; Kaplin, AI; Kerr, DA, 2007) |
| "Sarcoidosis is a systemic granulomatous disease that affects numerous organs, commonly manifesting at the lungs and skin." | 2.52 | TNF-α: a treatment target or cause of sarcoidosis? ( Amber, KT; Bloom, R; Hertl, M; Mrowietz, U, 2015) |
| "Lenalidomide therapy was initiated, and the patient's skin condition improved after 6 weeks of treatment; however, his MDS progressed to acute myeloid leukemia, and he died shortly thereafter." | 1.37 | Myelodysplastic syndrome presenting as generalized granulomatous dermatitis. ( Balin, SJ; Kurtin, PJ; Letendre, L; Pittelkow, MR; Wetter, DA, 2011) |
| "Thalidomide was used as treatment in colitis and arthritis group, whereas etoricoxib was used in CWG group." | 1.36 | Correlation of seizures and biochemical parameters of oxidative stress in experimentally induced inflammatory rat models. ( Khanduja, KL; Medhi, B; Pandhi, P; Rao, RS, 2010) |
| "Thalidomide is an immunomodulatory agent that acts to inhibit production of tumor-necrosis factor-alpha (TNF-alpha), an important mediator in CNS inflammation, by enhancing TNF-alpha mRNA degradation." | 1.34 | Thalidomide for acute treatment of neurosarcoidosis. ( Hammond, ER; Kaplin, AI; Kerr, DA, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kaushik, A | 1 |
| Kumaran, MS | 1 |
| Chatterjee, D | 1 |
| De, D | 1 |
| Amber, KT | 1 |
| Bloom, R | 1 |
| Mrowietz, U | 1 |
| Hertl, M | 1 |
| Weed, J | 1 |
| Ko, C | 1 |
| Stahl, M | 1 |
| Much, M | 1 |
| Witt, D | 1 |
| Zeidan, AM | 1 |
| Leventhal, J | 1 |
| Yazganoğlu, KD | 1 |
| Tambay, E | 1 |
| Mete, O | 1 |
| Ozkaya, E | 1 |
| Silapunt, S | 1 |
| Chon, SY | 1 |
| Rao, RS | 1 |
| Medhi, B | 1 |
| Khanduja, KL | 1 |
| Pandhi, P | 1 |
| Balin, SJ | 1 |
| Wetter, DA | 1 |
| Kurtin, PJ | 1 |
| Letendre, L | 1 |
| Pittelkow, MR | 1 |
| Moller, DR | 1 |
| Hegarty, A | 1 |
| Hodgson, T | 1 |
| Porter, S | 1 |
| Hodgson, TA | 1 |
| Buchanan, JA | 1 |
| Porter, SR | 1 |
| Tsuneki, H | 1 |
| Ma, EL | 1 |
| Kobayashi, S | 1 |
| Sekizaki, N | 1 |
| Maekawa, K | 1 |
| Sasaoka, T | 1 |
| Wang, MW | 1 |
| Kimura, I | 1 |
| Meier, F | 1 |
| Berner, D | 1 |
| Scherwitz, C | 1 |
| Rassner, G | 1 |
| Metzler, G | 1 |
| Hammond, ER | 1 |
| Kaplin, AI | 1 |
| Kerr, DA | 1 |
| Aarestrup, FM | 1 |
| Gonçalves-da-Costa, SC | 1 |
| Sarno, EN | 1 |
| Or, R | 1 |
| Feferman, R | 1 |
| Shoshan, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel[NCT02298491] | Phase 4 | 4 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total number of lesions assessed at 1 year (NCT02298491)
Timeframe: 1 year
| Intervention | lesions (Number) |
|---|---|
| H.P. Acthar Gel | 5 |
2 reviews available for thalidomide and Granulomas
| Article | Year |
|---|---|
TNF-α: a treatment target or cause of sarcoidosis?
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Etanercept; Granuloma; Hum | 2015 |
Treatment of sarcoidosis -- from a basic science point of view.
Topics: Etanercept; Granuloma; Humans; Immunoglobulin G; Immunosuppressive Agents; Interleukins; Pentoxifyll | 2003 |
13 other studies available for thalidomide and Granulomas
| Article | Year |
|---|---|
The Search for a Uniformly Effective Treatment in Patients With Lupus Miliaris Disseminatus Faciei.
Topics: Administration, Oral; Adult; Facial Dermatoses; Granuloma; Humans; Male; Phosphodiesterase 4 Inhibit | 2020 |
Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.
Topics: Aged; Blood Transfusion; Comorbidity; Fatal Outcome; Female; Granuloma; Histiocytes; Humans; Lenalid | 2017 |
Interstitial granulomatous drug reaction due to thalidomide.
Topics: Aged; Antibodies, Antinuclear; Female; Granuloma; Humans; Multiple Myeloma; Thalidomide | 2009 |
Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Dexamethasone; Granuloma; Humans; Lenalidomide; Male; Monoclonal Gammopathy | 2010 |
Correlation of seizures and biochemical parameters of oxidative stress in experimentally induced inflammatory rat models.
Topics: Animals; Arthritis, Experimental; Colitis; Disease Models, Animal; Granuloma; Inflammation; Lipid Pe | 2010 |
Myelodysplastic syndrome presenting as generalized granulomatous dermatitis.
Topics: Aged; Antineoplastic Agents; Biopsy; Blood Cell Count; Dermatitis; Disease Progression; Granuloma; H | 2011 |
Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis.
Topics: Adolescent; Child; Crohn Disease; Female; Follow-Up Studies; Granuloma; Humans; Immunosuppressive Ag | 2003 |
Orofacial granulomatosis.
Topics: Adrenal Cortex Hormones; Face; Granuloma; Humans; Immunosuppressive Agents; Injections, Intralesiona | 2004 |
Antiangiogenic activity of beta-eudesmol in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Astrocytes; Cell Adhesion; Cell Movement; Cell Proliferation; Cell | 2005 |
[An unusual case of pyoderma gangrenosum with necrotizing granulomatous dermatitis].
Topics: Dermatitis; Granuloma; Humans; Male; Middle Aged; Pyoderma Gangrenosum; Rare Diseases; Thalidomide; | 2003 |
Thalidomide for acute treatment of neurosarcoidosis.
Topics: Adult; Brain; Granuloma; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Proprio | 2007 |
The effect of thalidomide on BCG-induced granulomas in mice.
Topics: Animals; Female; Granuloma; Liver Diseases; Mice; Mycobacterium Infections; Thalidomide; Tumor Necro | 1995 |
Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs.
Topics: Animals; Cricetinae; DNA; Foreign-Body Reaction; Granuloma; Hydroxyproline; Male; Neovascularization | 1998 |